Adenosine triphosphate concentrations are higher in the brain of APOE3- compared to APOE4-targeted replacement mice and can be modulated by curcumin
© Springer-Verlag Berlin Heidelberg 2014
Received: 7 January 2014
Accepted: 12 March 2014
Published: 27 March 2014
Curcumin from Curcuma longa may exert putative neuroprotective properties in the brain. Impaired mitochondrial function is implicated in Alzheimer’s disease and the presence of the apolipoprotein (APO) E4 genotype, which is a risk factor for late-onset Alzheimer’s disease, may aggravate mitochondrial malfunction. Here, we report that in the brain of 16-month-old APOE4-targeted replacement mice, adenosine triphosphate (ATP) concentrations were significantly lower than in APOE3 mice. A 3-month dietary supplementation of 0.2 % curcumin numerically increased ATP concentrations in APOE3 and significantly in APOE4 mice compared to the respective controls. Curcumin significantly induced the transcription of peroxisome proliferator-activated receptor (PPAR) γ and mitochondrial transcription factor A (TFAM) in APOE3, but not in APOE4 mice. Moreover, PPARγ coactivator (PGC)-1α and guanine–adenine repeat binding protein α (GABPa) mRNA was only increased in APOE3 mice. Consistent with these observations, protein expression of mitochondrial respiratory complexes, especially of complex IV, also appeared to be increased in APOE3 mice. In conclusion, we provide evidence that curcumin affects mitochondrial function and gene and protein expression in the murine brain despite its low bioavailability and carriers of the Alzheimer’s disease-risk genotype APOE4 may be less responsive to dietary curcumin than APOE3 carriers.
Curcumin or diferuloylmethane makes up 50–60 % of the total curcuminoids isolated from Curcuma longa (family Zingiberaceae) and is chemically a bis-α,β-unsaturated β-diketone of two ferulic acid units (Esatbeyoglu et al. 2012; Chin et al. 2013). Curcumin has been attributed with neuroprotective potential and the Indo-US Cross National Dementia Study reported that India had a lower incidence and a lower prevalence of Alzheimer’s disease (AD) compared to a reference American population (Chandra et al. 1998, 2001). To date, there have been two completed clinical trials investigating the neuroprotective efficacy of curcumin with regard to AD, but both studies have not reported significant neuroprotective effects (Baum et al. 2008; Ringman et al. 2012). One possible explanation for the lack of neuroprotective efficacy may be the low bioavailability of curcumin. Curcumin, being a fat soluble molecule, exhibits poor aqueous solubility, poor stability in solution, and rapid intestinal and hepatic metabolism (Anand et al. 2007). Due to its low toxicity, many studies are administering high doses of curcumin in the hope of increasing its concentration in the brain. We have previously reported that curcumin cannot be detected in the brain of NMRI mice after oral administration of 50 mg/kg BW curcumin (Schiborr et al. 2010). However, a recent report from Japan observed that behavioural symptoms of patients with AD could be improved by applying a low dose of approximately 100 mg/day curcumin (Hishikawa et al. 2012). This suggests that even very small concentrations of curcumin or curcumin metabolites below the analytical detection limit may induce effects on the molecular level (neuro- or mitohormesis) and account for the observed neuroprotective effects (Mattson and Cheng 2006; Calabrese et al. 2010).
The apolipoprotein (APO) E4 allele is a major genetic risk factor for sporadic or late-onset AD (Strittmatter and Roses 1996; Jofre-Monseny et al. 2008). APOE is involved in the distribution and cellular uptake of cholesterol and is the major apolipoprotein in the brain (Huebbe et al. 2007). Although the exact mechanism through which APOE4 contributes to an increased risk of AD is as yet unclear, it is likely that APOE is involved in many different mechanisms that contribute to AD. One of these mechanisms might involve mitochondrial function. Mitochondrial dysfunction has been observed repeatedly in AD and favours inflammation and cell loss, which are central events in the pathogenesis of AD (Hauptmann et al. 2009). Decreased expression of mitochondrial respiratory complexes and lowered mitochondrial respiratory capacity, as observed in the cortex of APOE4 mice, could further promote mitochondrial dysfunction and therefore contribute to AD (Chen et al. 2011). Interestingly, it has recently been shown that mitochondrial dysfunction associated with APOE4 could be improved by small molecule structure correctors which inhibit the domain interaction of APOE4 involved in mediating its detrimental effects (Chen et al. 2012).
We have previously reported that dietary curcumin can modulate markers of mitochondrial dysfunction in the brain of senescence-accelerated mouse prone 8 (Eckert et al. 2013). Despite widespread interest in curcumin as a potential therapeutic or preventive agent for neurodegenerative diseases (Eckert et al. 2012), to the best of our knowledge, the neuroprotective efficacy of curcumin has never been investigated in the context of APOE. We hypothesised that dietary curcumin might increase adenosine triphosphate (ATP) concentrations and modulate genes involved in the regulation of mitochondrial biogenesis and function in the cortex of APOE3- and APOE4-targeted gene replacement mice.
Materials and methods
Mice and diet
Female APOE3- and APOE4-targeted gene replacement mice aged 6–8 weeks old were purchased from Taconic Europe (Ry, Denmark). APOE-targeted gene replacement mice were originally developed at the laboratory of Nobuya Maeda and are well characterized (Knouff et al. 1999; Sullivan et al. 1997, 1998). A detailed description of how these mice were created can be found in our previous publication (Huebbe et al. 2011). Briefly, the murine APOE gene was targeted in E14TG2a embryonic stem cells for replacement with the human APOE alleles. The targeted cells were injected into blastocytes, and the resultant chimeras were backcrossed to C57BL/6 mice for 9 generations. Colonies (N9) are maintained at Taconic through in-crossing of homozygotes.
The animal study was performed according to German animal welfare laws and regulations, and with permission from the responsible authorities. The mice were housed in macrolon cages under controlled environmental conditions (55 % relative humidity, 22–24 °C, and 12-h light–dark cycle). The mice were maintained on a semi-synthetic Western-type diet (C1000 mod., Altromin, Lage, Germany) containing 40 % carbohydrate, 18 % protein, 20 % milk fat, 1.25 % cholesterol, as well as a vitamin and mineral premix. The mice had free access to tap water. For the first 11 months, all mice were fed the Western-type diet ad libitum. Afterwards, the mice were randomly assigned to two diet groups (control and 0.2 % curcumin-supplemented). The supplementation period was 3 months, during which both groups were given ad libitum access to the respective diets. At the end of the trial, the mice were fasted for 12 h and killed by cervical dislocation. For the ATP measurements, dissociated brain cells were freshly prepared (Eckert et al. 2013), and for the other measurements, parts of the cortex were stored in RNAlater™ (Qiagen, Hilden, Germany) at −20 °C or snap-frozen in liquid nitrogen and stored at −80 °C.
Preparation of dissociated brain cells
One brain hemisphere was used for the preparation of dissociated brain cells and quickly dissected on ice after removal. The cerebellum was excluded and the remaining tissue was first washed, and then minced in 2 mL of medium I (138 mM NaCl, 5.4 mM KCl, 0.17 mM Na2HPO4, 0.22 mM KH2PO4, 5.5 mM glucose, 58.4 mM sucrose, pH 7.35) with a scalpel. The brain cells were further dissociated first by filtration through a crude filter using a Pasteur pipette and later through a fine filter. The cell suspension was then washed twice in medium II (110 mM NaCl, 5.3 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 25 mM glucose, 70 mM sucrose, 20 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), pH 7.4). After a final centrifugation step (1,000g, 5 min, 4 °C), the cell pellet was resuspended in 4.5 mL Dulbecco’s modified Eagle’s medium (Gibco®, Invitrogen, Germany) and distributed 50 μL/well in white 96-well plates for ATP measurements. Plated dissociated brain cells were incubated at 37 °C in 5 % CO2 for 3 h prior to measurement. ATP concentrations are expressed as fluorescence per milligram protein, and the protein content was determined using the Bio-Rad DC Protein Assay (Bio-Rad, Munich, Germany).
Measurement of ATP concentrations
Basal ATP concentrations were measured using the Via Light™ Plus Bioluminescence Kit (Lonza, Walkersville, USA) according to the manufacturer’s protocol. The Via Light™ Plus Kit is based on the production of light from ATP and luciferin in the presence of luciferase. The emitted light (bioluminescence) correlates linearly with ATP concentration and can be determined using an external standard curve. Briefly, dissociated brain cells were removed from the incubator and allowed to cool to room temperature for 10 min. After that, cells were lysed with the provided lysis reagent for 10 min and then incubated with the ATP monitoring reagent for 5 min. Measurements were carried out in a Tecan Infinite F200 microplate reader (Tecan Group Ltd., Crailsheim, Germany). At least five animals per group were included for the measurement.
RNA isolation and quantitative real-time polymerase chain reaction (RT-PCR)
Nucleotide sequences (5′–3′) of murine primers used for the quantitative real-time PCR
Primer sequence forward
Primer sequence reverse
Whole cell lysates of murine cortex were used to investigate the protein concentrations of mitochondrial complexes. Protein concentrations were first determined using the Pierce BCA protein assay kit (Thermo Scientific, Rockford, USA). Samples were mixed with Tris/glycine reducing buffer and denaturing loading buffer (both from Invitrogen™, Germany). Subsequently, the samples were loaded and electrophoresed on NuPAGE 4–12 % Bis–Tris Gels (Invitrogen™, Germany). Proteins were then transferred to PVDF membranes (Amersham Biosciences) and incubated with the respective primary antibodies: MitoProfile Total OXPHOS (ab110411), complex IV (ab110259) (both from Abcam, Cambridge, UK) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (MAB374) (Millipore, Billerica, USA), and secondary antibodies (Calbiochem, Germany) conjugated with horseradish peroxidase. The bands were then visualized by using ECL Plus reagent (Amersham Biosciences). GAPDH served as a loading control. At least three animals per group were included for the measurement, and two replicates of each measurement were carried out. Band analysis was performed using BioRad’s Quantity One software.
Measurement of proteasomal activity
Proteasomal activity was assayed as described previously by Stolzing and Grune (Stolzing and Grune 2003) with minor modifications. At least three animals per group were included for the measurement. Cortex tissue was homogenized in 20 μL lysis buffer (250 mM sucrose, 25 mM HEPES, 10 mM MgCl2, 1 mM EDTA, and 1.7 mM dithiothreitol (DTT)) per milligram tissue. Following homogenization, cells were centrifuged at 4 °C and 15,000g for 25 min and the supernatants were used for protein determination using Bradford assay and for proteasomal activity measurement. For proteasomal activity, the supernatants were incubated in 225 mM Tris buffer (pH 7.8), 45 mM KCl, 7.5 mM magnesium acetate, 7.5 mM MgCl2, and 1 mM DTT. To measure chymotrypsin-like activity of the proteasome, the fluorogenic peptide Suc-LLVY-MCA was used as a substrate at a concentration of 200 μM. Samples were incubated for 30 min at 37 °C, followed by MCA liberation measurements with a fluorescence reader (Reader EL 340, BioTek Instruments, Bad Friendrichshall, Germany) at 360-nm excitation and 460-nm emission. Free MCA was used as the standard for quantification.
Statistical analysis was performed using SPSS version 19.0 (SPSS GmbH Software, Munich, Germany). Normal distribution of data was tested by Kolmogorov–Smirnov and Shapiro–Wilk tests. Normally distributed data were analysed using Student’s t test. In cases where data were not normally distributed, Mann–Whitney U test was performed. Results are presented as mean ± SEM. p values <0.05 were considered statistically significant.
Curcumin supplementation increased ATP concentrations in the brain
Curcumin supplementation differentially regulated transcription factors involved in mitochondrial biogenesis in APOE3 and APOE4 mice
Curcumin supplementation increased protein concentrations of mitochondrial respiratory complexes in the cortex
Proteasomal activity in the cortex did not differ between curcumin-supplemented and control APOE3 and APOE4 mice
Despite widespread interest in curcumin as a potential therapeutic or preventive agent for neurodegenerative diseases, the neuroprotective efficacy of curcumin has not been investigated in the context of APOE even though APOE4 is a major genetic risk factor for late-onset AD. The principal finding of our study is that dietary curcumin supplementation may increase ATP concentrations in the brain of APOE3- and APOE4-targeted gene replacement mice, which is in agreement with our previous observations in SAMP8 mice (Eckert et al. 2013). Moreover, our APOE4 mice showed significantly lower ATP concentrations compared to APOE3 mice, which is consistent with the previous observation of lowered mitochondrial respiratory capacity in the cortex of APOE4 mice (Chen et al. 2011). We also observed that APOE4 mice had increased concentrations of mitochondrial superoxide dismutase 2 (data not shown), which might be indicative of increased oxidative damage as previously observed in patients with AD carrying the APOE4 allele (Tayler et al. 2010). Contrarily, we did not observe any changes in the proteasomal activity in the cortex although curcumin has been reported to modulate proteasomal degradation (Dikshit et al. 2006; Hasima and Aggarwal 2013).
Interestingly, our attempt to identify potential underlying mechanisms revealed that curcumin induced the expression of transcription factors (PPARγ, GABPa, and TFAM) and coactivators (PGC1α) of mitochondrial biogenesis in APOE3 mice. However, this was not the case for APOE4 mice since the expression of three out of four of these genes did not increase in response to curcumin. With the exception of PGC1α, the expression of PPARγ, GABPa, and TFAM remained unchanged or was even decreased in curcumin-fed APOE4 mice. The induction of PGC1α by curcumin in APOE3 and APOE4 mice confirms our previous observations in SAMP8 mice fed curcumin for 5 months (Eckert et al. 2013). PGC1α is considered the master regulator of mitochondrial biogenesis and function (Puigserver and Spiegelman 2003), modulating the expression of other transcription factors such as PPARγ, NRF1, and GABPa (Wu et al. 1999). Therefore, the curcumin-induced, albeit minor, increase in PGC1α mRNA may at least partly account for the higher ATP concentrations in curcumin-fed mice of both genotypes, APOE3 and APOE4.
Our data suggest that at least some of the effects of curcumin are less pronounced in APOE4 compared to APOE3 mice and thus that APOE3 is more responsive to dietary curcumin intervention. This is in accordance with our previous findings that APOE4 mice are less sensitive to dietary intervention with vitamin E and quercetin than APOE3 mice (Huebbe et al. 2007; Boesch-Saadatmandi et al. 2009).
We have previously shown that oral gavage of 50 mg/kg BW curcumin did not lead to detectable amounts of curcumin in the brain (Schiborr et al. 2010). Nevertheless, these data suggest that curcumin could affect mitochondrial function in the cortex despite its low bioavailability. This is consistent with previous observations that curcumin prevented mitochondrial dysfunction in the brain of senescence-accelerated mice (Eckert et al. 2013). The finding that curcumin induced a positive response in the cortex although it could not be detected in these tissues suggests that curcumin may exert secondary effects without being physically present in the brain. Previously, curcumin metabolites such as ferulic and vanillic acid have been shown to be enriched in serum upon application of curcumin and could therefore contribute to its metabolic effects (Vitaglione et al. 2012). Furthermore, it has been shown that curcumin is an iron chelator and could interact with iron metabolism (Chin et al. 2014; Jiao et al. 2009), thus modulating mitochondrial function. The possibility that local antimicrobial effects of curcumin (Bhawana et al. 2011) might modify the oral or gut microflora which could then trigger systemic alterations and exert effects on the brain is also particularly interesting. In fact, there are indications that the oral microflora may influence the pathology of AD. Certain strains of periodontal pathogens have been found more frequently in AD brains, and serum levels of antibodies against common periodontal pathogens have been associated with an increased risk of developing AD (Riviere et al. 2002; Kamer et al. 2009; Sparks Stein et al. 2012). Alternatively, the concept of hormesis which describes the adaptive process where exposure to a (very) low dose of a stimulus can activate cellular stress response pathways and thereby increase the ability to cope with more severe stress (Mattson and Cheng 2006; Calabrese et al. 2010) may also explain the observed effects of curcumin. According to this concept, even very low curcumin brain concentration could affect gene and protein expression and improve the organism’s stress response (Mattson and Cheng 2006; Calabrese et al. 2010).
In conclusion, we provide evidence that dietary curcumin affects gene and protein expression in the murine brain despite its low bioavailability. Furthermore, with regard to mitochondrial function and ATP synthesis, our data support the notion that the APOE3 genotype may be more responsive to dietary curcumin intervention compared to the APOE4 genotype.
We are grateful to the German Federal Ministry of Education and Research (BMBF) for financial support (Grant # 0315679).
Conflict of interest
Dawn Chin, Stephanie Hagl, Annika Hoehn, Patricia Huebbe, Kathrin Pallauf, Tilman Grune, Jan Frank, Gunter P. Eckert, and Gerald Rimbach declare that they have no conflict of interest.
All institutional and national guidelines for the care and use of laboratory animals were followed.
- Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4(6):807–818. doi:10.1021/mp700113r PubMedView ArticleGoogle Scholar
- Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28(1):110–113. doi:10.1097/jcp.0b013e318160862c PubMedView ArticleGoogle Scholar
- Bhawana Basniwal RK, Buttar HS, Jain VK, Jain N (2011) Curcumin nanoparticles: preparation, characterization, and antimicrobial study. J Agric Food Chem 59(5):2056–2061. doi:10.1021/jf104402t PubMedView ArticleGoogle Scholar
- Boesch-Saadatmandi C, Wolffram S, Minihane AM, Rimbach G (2009) Effect of apoE genotype and dietary quercetin on blood lipids and TNF-alpha levels in apoE3 and apoE4 targeted gene replacement mice. Br J Nutr 101(10):1440–1443. doi:10.1017/S0007114508102434 PubMedView ArticleGoogle Scholar
- Calabrese V, Cornelius C, Dinkova-Kostova AT, Calabrese EJ, Mattson MP (2010) Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal 13(11):1763–1811. doi:10.1089/ars.2009.3074 PubMed CentralPubMedView ArticleGoogle Scholar
- Chandra V, Ganguli M, Pandav R, Johnston J, Belle S, DeKosky ST (1998) Prevalence of Alzheimer’s disease and other dementias in rural India: the Indo-US study. Neurology 51(4):1000–1008PubMedView ArticleGoogle Scholar
- Chandra V, Pandav R, Dodge HH, Johnston JM, Belle SH, DeKosky ST, Ganguli M (2001) Incidence of Alzheimer’s disease in a rural community in India: the Indo-US study. Neurology 57(6):985–989PubMedView ArticleGoogle Scholar
- Chen HK, Ji ZS, Dodson SE, Miranda RD, Rosenblum CI, Reynolds IJ, Freedman SB, Weisgraber KH, Huang Y, Mahley RW (2011) Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. J Biol Chem 286(7):5215–5221. doi:10.1074/jbc.M110.151084 PubMed CentralPubMedView ArticleGoogle Scholar
- Chen HK, Liu Z, Meyer-Franke A, Brodbeck J, Miranda RD, McGuire JG, Pleiss MA, Ji ZS, Balestra ME, Walker DW, Xu Q, Jeong DE, Budamagunta MS, Voss JC, Freedman SB, Weisgraber KH, Huang Y, Mahley RW (2012) Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. J Biol Chem 287(8):5253–5266. doi:10.1074/jbc.M111.276162 PubMed CentralPubMedView ArticleGoogle Scholar
- Chin D, Huebbe P, Pallauf K, Rimbach G (2013) Neuroprotective properties of curcumin in Alzheimer’s disease–merits and limitations. Curr Med Chem 20(32):3955–3985PubMedView ArticleGoogle Scholar
- Chin D, Huebbe P, Frank J, Rimbach G, Pallauf K (2014) Curcumin may impair iron status when fed to mice for six months. Redox Biology. doi:http://dx.doi.org/10.1016/j.redox.2014.01.018
- Dikshit P, Goswami A, Mishra A, Chatterjee M, Jana NR (2006) Curcumin induces stress response, neurite outgrowth and prevent NF-kappaB activation by inhibiting the proteasome function. Neurotox Res 9(1):29–37PubMedView ArticleGoogle Scholar
- Eckert GP, Renner K, Eckert SH, Eckmann J, Hagl S, Abdel-Kader RM, Kurz C, Leuner K, Muller WE (2012) Mitochondrial dysfunction—a pharmacological target in Alzheimer’s disease. Mol Neurobiol 46(1):136–150. doi:10.1007/s12035-012-8271-z PubMedView ArticleGoogle Scholar
- Eckert GP, Schiborr C, Hagl S, Abdel-Kader R, Muller WE, Rimbach G, Frank J (2013) Curcumin prevents mitochondrial dysfunction in the brain of the senescence-accelerated mouse-prone 8. Neurochem Int 62(5):595–602. doi:10.1016/j.neuint.2013.02.014 PubMedView ArticleGoogle Scholar
- Esatbeyoglu T, Huebbe P, Ernst IM, Chin D, Wagner AE, Rimbach G (2012) Curcumin—from molecule to biological function. Angew Chem Int Ed Engl 51(22):5308–5332. doi:10.1002/anie.201107724 PubMedView ArticleGoogle Scholar
- Hasima N, Aggarwal BB (2013) Targeting proteasomal pathways by dietary curcumin for cancer prevention and treatment. Curr Med Chem. doi:10.2174/09298673113206660135
- Hauptmann S, Scherping I, Drose S, Brandt U, Schulz KL, Jendrach M, Leuner K, Eckert A, Muller WE (2009) Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 30(10):1574–1586. doi:10.1016/j.neurobiolaging.2007.12.005 PubMedView ArticleGoogle Scholar
- Hishikawa N, Takahashi Y, Amakusa Y, Tanno Y, Tuji Y, Niwa H, Murakami N, Krishna UK (2012) Effects of turmeric on Alzheimer’s disease with behavioral and psychological symptoms of dementia. Ayu 33(4):499–504. doi:10.4103/0974-8520.110524 PubMed CentralPubMedView ArticleGoogle Scholar
- Hondares E, Mora O, Yubero P, Rodriguez de la Concepcion M, Iglesias R, Giralt M, Villarroya F (2006) Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptor-coactivator (PGC)-1alpha gene transcription: an autoregulatory loop controls PGC-1alpha expression in adipocytes via peroxisome proliferator-activated receptor-gamma coactivation. Endocrinology 147(6):2829–2838. doi:http://www.ncbi.nlm.nih.gov/pubmed/16513826 PubMedView ArticleGoogle Scholar
- Huebbe P, Jofre-Monseny L, Boesch-Saadatmandi C, Minihane AM, Rimbach G (2007) Effect of apoE genotype and vitamin E on biomarkers of oxidative stress in cultured neuronal cells and the brain of targeted replacement mice. J Physiol Pharmacol 58(4):683–698PubMedGoogle Scholar
- Huebbe P, Nebel A, Siegert S, Moehring J, Boesch-Saadatmandi C, Most E, Pallauf J, Egert S, Muller MJ, Schreiber S, Nothlings U, Rimbach G (2011) APOE epsilon4 is associated with higher vitamin D levels in targeted replacement mice and humans. FASEB J 25(9):3262–3270. doi:10.1096/fj.11-180935 PubMedView ArticleGoogle Scholar
- Jiao Y, Wilkinson JT, Di X, Wang W, Hatcher H, Kock ND, D’Agostino R Jr, Knovich MA, Torti FM, Torti SV (2009) Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood 113(2):462–469. doi:10.1182/blood-2008-05-155952 PubMed CentralPubMedView ArticleGoogle Scholar
- Jofre-Monseny L, Minihane AM, Rimbach G (2008) Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res 52(1):131–145. doi:10.1002/mnfr.200700322 PubMedView ArticleGoogle Scholar
- Kamer AR, Craig RG, Pirraglia E, Dasanayake AP, Norman RG, Boylan RJ, Nehorayoff A, Glodzik L, Brys M, de Leon MJ (2009) TNF-alpha and antibodies to periodontal bacteria discriminate between Alzheimer’s disease patients and normal subjects. J Neuroimmunol 216(1–2):92–97. doi:10.1016/j.jneuroim.2009.08.013 PubMed CentralPubMedView ArticleGoogle Scholar
- Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, Sullivan PM, Maeda N (1999) Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest 103(11):1579–1586. doi:10.1172/JCI6172 PubMed CentralPubMedView ArticleGoogle Scholar
- Mattson MP, Cheng A (2006) Neurohormetic phytochemicals: low-dose toxins that induce adaptive neuronal stress responses. Trends Neurosci 29(11):632–639. doi:10.1016/j.tins.2006.09.001 PubMedView ArticleGoogle Scholar
- Ongwijitwat S, Liang HL, Graboyes EM, Wong-Riley MT (2006) Nuclear respiratory factor 2 senses changing cellular energy demands and its silencing down-regulates cytochrome oxidase and other target gene mRNAs. Gene 374:39–49. doi:http://www.ncbi.nlm.nih.gov/pubmed/16516409 PubMedView ArticleGoogle Scholar
- Puigserver P, Spiegelman BM (2003) Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 24(1):78–90PubMedView ArticleGoogle Scholar
- Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92(6):829–839PubMedView ArticleGoogle Scholar
- Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, Montine TJ, Cummings JL, Cole GM (2012) Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther 4(5):43. doi:http://alzres.com/content/4/5/43 PubMed CentralPubMedView ArticleGoogle Scholar
- Rinwa P, Kaur B, Jaggi AS, Singh N (2010) Involvement of PPAR-gamma in curcumin-mediated beneficial effects in experimental dementia. Naunyn Schmiedebergs Arch Pharmacol 381(6):529–539. doi:10.1007/s00210-010-0511-z PubMedView ArticleGoogle Scholar
- Riviere GR, Riviere KH, Smith KS (2002) Molecular and immunological evidence of oral treponema in the human brain and their association with Alzheimer’s disease. Oral Microbiol Immunol 17(2):113–118. doi:http://www.ncbi.nlm.nih.gov/pubmed/11929559 PubMedView ArticleGoogle Scholar
- Schiborr C, Eckert GP, Rimbach G, Frank J (2010) A validated method for the quantification of curcumin in plasma and brain tissue by fast narrow-bore high-performance liquid chromatography with fluorescence detection. Anal Bioanal Chem 397(5):1917–1925. doi:10.1007/s00216-010-3719-3 PubMedView ArticleGoogle Scholar
- Sparks Stein P, Steffen MJ, Smith C, Jicha G, Ebersole JL, Abner E, Dawson D 3rd (2012) Serum antibodies to periodontal pathogens are a risk factor for Alzheimer’s disease. Alzheimers Dement 8(3):196–203. doi:10.1016/j.jalz.2011.04.006 PubMedView ArticleGoogle Scholar
- Stolzing A, Grune T (2003) Impairment of protein homeostasis and decline of proteasome activity in microglial cells from adult Wistar rats. J Neurosci Res 71(2):264–271. doi:10.1002/jnr.10478 PubMedView ArticleGoogle Scholar
- Strittmatter WJ, Roses AD (1996) Apolipoprotein E and Alzheimer’s disease. Annu Rev Neurosci 19:53–77. doi:10.1146/annurev.ne.19.030196.000413 PubMedView ArticleGoogle Scholar
- Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 272(29):17972–17980PubMedView ArticleGoogle Scholar
- Sullivan PM, Mezdour H, Quarfordt SH, Maeda N (1998) Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest 102(1):130–135. doi:10.1172/JCI2673 PubMed CentralPubMedView ArticleGoogle Scholar
- Tayler H, Fraser T, Miners JS, Kehoe PG, Love S (2010) Oxidative balance in Alzheimer’s disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-beta. J Alzheimers Dis 22(4):1363–1373. doi:10.3233/JAD-2010-101368 PubMedGoogle Scholar
- Vitaglione P, Barone Lumaga R, Ferracane R, Radetsky I, Mennella I, Schettino R, Koder S, Shimoni E, Fogliano V (2012) Curcumin bioavailability from enriched bread: the effect of microencapsulated ingredients. J Agric Food Chem 60(13):3357–3366. doi:10.1021/jf204517k PubMedView ArticleGoogle Scholar
- Wang HM, Zhao YX, Zhang S, Liu GD, Kang WY, Tang HD, Ding JQ, Chen SD (2010) PPARgamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes. J Alzheimers Dis 20(4):1189–1199. doi:10.3233/JAD-2010-091336 PubMedGoogle Scholar
- Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98(1):115–124. doi:10.1016/S0092-8674(00)80611-X PubMedView ArticleGoogle Scholar